---
schema_version: "secwatch.filing_event.v1"
accession: "0001815776-25-000054"
form_type: "8-K"
ticker: "LENZ"
cik: "0001815776"
company_name: "LENZ Therapeutics, Inc."
filed_at: "2025-07-30T23:59:59+00:00"
generated_at: "2026-05-17T23:10:22.612711+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# LENZ reports Q2 net loss $14.9M; LNZ100 PDUFA on track for Aug 8, 2025

## Summary
- Cash, cash equivalents and marketable securities $209.6M as of June 30, 2025; >$205M expected by PDUFA date.
- Net loss $14.9M ($0.53 per share) for Q2 2025 vs $10.3M ($0.40) in Q2 2024.
- NDA for LNZ100 (aceclidine for presbyopia) under FDA review; PDUFA target Aug 8, 2025; no advisory committee.
- Commercial team of 88 sales force hired and trained; launch ready upon FDA approval.
- Executed multiple international license deals totaling >$195M potential milestones plus double-digit royalties.

## SEC filing metadata
- accession: 0001815776-25-000054
- form_type: 8-K
- ticker: LENZ
- cik: 0001815776
- company_name: LENZ Therapeutics, Inc.
- filed_at: 2025-07-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815776/000181577625000054/0001815776-25-000054-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815776/000181577625000054/lenz-20250730.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001815776-25-000054
- JSON: https://secwatch.observer/filing/0001815776-25-000054.json
- Plain text: https://secwatch.observer/filing/0001815776-25-000054.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.